Tearsheet

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%
Weak multi-year price returns
2Y Excs Rtn is -74%, 3Y Excs Rtn is -88%
 
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30%
  
2 Attractive yield
FCF Yield is 5.6%
  
3 Low stock price volatility
Vol 12M is 29%
  
4 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Water Infrastructure. Themes include Geriatric Care, and Wastewater Management.
  
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30%
2 Attractive yield
FCF Yield is 5.6%
3 Low stock price volatility
Vol 12M is 29%
4 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Water Infrastructure. Themes include Geriatric Care, and Wastewater Management.
5 Weak multi-year price returns
2Y Excs Rtn is -74%, 3Y Excs Rtn is -88%

Valuation, Metrics & Events

CHE Stock


Why The Stock Moved


Qualitative Assessment

AI Generated Analysis | Feedback

Here are five key points explaining Chemed's stock movement by -5.8% during the approximate time period from August 31, 2025, to December 4, 2025: 1. Chemed's Second Quarter 2025 Earnings Miss. Although reported just before the specified period on July 29, 2025, Chemed's second-quarter earnings significantly missed analyst expectations for both earnings per share (EPS) and revenue, leading to an 8.8% stock price drop in after-hours trading. The company also revised its full-year 2025 EPS guidance downward from previous estimates, setting a cautious tone that likely influenced sentiment in the early part of the August-December timeframe.

2. Third Quarter 2025 Adjusted EPS and EBITDA Miss. For the third quarter of 2025, reported on October 28, Chemed's adjusted diluted EPS of $5.27 fell below analysts' consensus estimates. Additionally, the adjusted EBITDA of $109 million missed analyst expectations of $113.9 million, indicating a decline in operational profitability.

Show more

Stock Movement Drivers

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
CHE Return22%-0%-3%15%-9%-19%-0%
Peers Return1%48%-7%28%7%43%172%
S&P 500 Return16%27%-19%24%23%16%112%

Monthly Win Rates [3]
CHE Win Rate58%58%42%67%58%40% 
Peers Win Rate43%62%48%55%52%70% 
S&P 500 Win Rate58%75%42%67%75%70% 

Max Drawdowns [4]
CHE Max Drawdown-20%-23%-18%-4%-11%-22% 
Peers Max Drawdown-40%-4%-25%-14%-15%-10% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: THC, WTS, NHC, CVS, CI. See CHE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)

How Low Can It Go

Unique KeyEventCHES&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-26.7%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven36.4%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven547 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-30.7%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven44.3%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven139 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-20.2%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven25.4%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven127 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-54.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven120.1%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven930 days1480 days

Compare to THC, WTS, NHC, CVS, CI


In The Past

Chemed's stock fell -26.7% during the 2022 Inflation Shock from a high on 1/25/2021. A -26.7% loss requires a 36.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Chemed (CHE)

Better Bets than Chemed (CHE)

Latest Trefis Analyses

Trade Ideas

Select past ideas related to CHE. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
4.1%4.1%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-9.8%-9.8%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
6.0%6.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.7%9.7%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
6.2%6.2%-5.1%
CHE_2292020_Quality_Momentum_RoomToRun_10%02292020CHEChemedQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run
22.5%6.9%-15.8%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
4.1%4.1%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-9.8%-9.8%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
6.0%6.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.7%9.7%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
6.2%6.2%-5.1%
CHE_2292020_Quality_Momentum_RoomToRun_10%02292020CHEChemedQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run
22.5%6.9%-15.8%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for Chemed

Peers to compare with:

Financials

CHETHCWTSNHCCVSCIMedian
NameChemed Tenet He.Watts Wa.National.CVS Heal.Cigna  
Mkt Price430.83211.34274.97137.6875.00268.81240.07
Mkt Cap6.218.69.22.195.271.613.9
Rev LTM2,53120,8462,3541,501394,084261,22011,688
Op Inc LTM3523,34744712410,751-447
FCF LTM3601,5023441476,2933,944931
FCF 3Y Avg3111,6783181046,4277,773998
CFO LTM4202,4783871819,1095,2921,449
CFO 3Y Avg3682,5503521339,2779,1971,459

Growth & Margins

CHETHCWTSNHCCVSCIMedian
NameChemed Tenet He.Watts Wa.National.CVS Heal.Cigna  
Rev Chg LTM6.5%-0.6%4.2%22.1%6.8%20.9%6.6%
Rev Chg 3Y Avg5.9%3.1%6.5%11.9%7.7%13.6%7.1%
Rev Chg Q3.1%3.2%12.5%12.5%7.8%11.2%9.5%
QoQ Delta Rev Chg LTM0.7%0.8%3.0%2.9%1.9%2.7%2.3%
Op Mgn LTM13.9%16.1%19.0%8.3%2.7%-13.9%
Op Mgn 3Y Avg14.5%13.8%17.8%6.2%3.3%-13.8%
QoQ Delta Op Mgn LTM-0.8%0.4%0.1%0.3%0.1%-0.1%
CFO/Rev LTM16.6%11.9%16.4%12.1%2.3%2.0%12.0%
CFO/Rev 3Y Avg15.4%12.3%16.0%10.2%2.5%4.4%11.3%
FCF/Rev LTM14.2%7.2%14.6%9.8%1.6%1.5%8.5%
FCF/Rev 3Y Avg13.0%8.1%14.4%7.9%1.8%3.8%8.0%

Valuation

CHETHCWTSNHCCVSCIMedian
NameChemed Tenet He.Watts Wa.National.CVS Heal.Cigna  
Mkt Cap6.218.69.22.195.271.613.9
P/S2.50.94.01.30.20.31.1
P/EBIT17.35.021.613.016.09.214.5
P/E23.113.228.818.6204.015.320.8
P/CFO15.47.224.210.410.514.512.5
Total Yield4.7%7.6%4.2%7.4%4.0%8.6%6.0%
Dividend Yield0.4%0.0%0.7%2.0%3.5%2.1%1.4%
FCF Yield 3Y Avg4.1%13.5%4.5%6.7%7.1%9.0%6.9%
D/E0.00.70.00.10.90.40.2
Net D/E0.00.6-0.0-0.10.70.30.2

Returns

CHETHCWTSNHCCVSCIMedian
NameChemed Tenet He.Watts Wa.National.CVS Heal.Cigna  
1M Rtn-2.1%4.9%1.4%13.7%-4.4%3.9%2.6%
3M Rtn-6.1%13.1%-0.1%23.3%3.1%-10.5%1.5%
6M Rtn-23.1%24.4%15.3%33.4%20.2%-12.9%17.8%
12M Rtn-23.6%49.6%29.6%12.5%32.1%-18.2%21.0%
3Y Rtn-16.9%366.7%76.1%149.4%-18.0%-13.4%31.3%
1M Excs Rtn-2.1%5.0%1.4%13.8%-4.4%4.0%2.7%
3M Excs Rtn-11.5%4.4%-6.9%14.8%-2.7%-16.9%-4.8%
6M Excs Rtn-37.8%9.7%0.5%18.7%5.5%-27.6%3.0%
12M Excs Rtn-37.9%34.6%14.9%-1.0%17.1%-32.5%7.0%
3Y Excs Rtn-87.5%302.5%12.7%72.9%-89.0%-84.1%-35.7%

Financials

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
VITAS1,3151,2021,2611,3351,281
Roto-Rooter949933878745657
Corporate00   
Total2,2642,1352,1392,0801,939


Operating Income by Segment
$ Mil20242023202220212020
Roto-Rooter227 211151 
VITAS184 196295 
Corporate-70 -64-57 
Total341 343390 


Net Income by Segment
$ Mil20242023202220212020
Roto-Rooter188186166120104
VITAS159131162239156
Corporate-74-68-60-40-40
Total273250269319220


Assets by Segment
$ Mil20242023202220212020
VITAS779750693672663
Roto-Rooter523512513499507
Corporate36617913626497
Total1,6681,4421,3431,4351,268


Price Behavior

Short Interest

Short Interest: As Of Date11142025
Short Interest: Shares Quantity683,710
Short Interest: % Change Since 103120256.2%
Average Daily Volume160,690
Days-to-Cover Short Interest4.25
Basic Shares Quantity14,394,000
Short % of Basic Shares4.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251031202510-Q 9/30/2025
6302025731202510-Q 6/30/2025
3312025428202510-Q 3/31/2025
12312024228202510-K 12/31/2024
93020241101202410-Q 9/30/2024
6302024726202410-Q 6/30/2024
3312024429202410-Q 3/31/2024
12312023229202410-K 12/31/2023
93020231027202310-Q 9/30/2023
6302023728202310-Q 6/30/2023
3312023428202310-Q 3/31/2023
12312022227202310-K 12/31/2022
93020221102202210-Q 9/30/2022
6302022729202210-Q 6/30/2022
3312022429202210-Q 3/31/2022
12312021228202210-K 12/31/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value
Value of
Held Shares
Form
0MCNAMARA KEVIN Jpresident and CEO11252025Sell437.552,000875,10041,215,897Form